Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qijian Granules
- Development stage
- Unknown
- Lead developer
- Consun Pharmaceutical
- Administration
- Oral
01
Overview
Qijian Granules (芪箭颗粒), also known as Tangshenfang (糖肾方), is a Traditional Chinese Medicine (TCM) candidate developed by Conchen Pharmaceutical (a subsidiary of Consun Pharmaceutical Group) for the treatment of diabetic kidney disease (DKD). Formulated as oral granules, it is designed to slow the progression of renal impairment in diabetic patients. The drug received approval for clinical trials from the China National Medical Products Administration (NMPA) in March 2018 and is currently in Phase 1 clinical development.
- Other names
- 芪箭颗粒糖肾方Tangshenfang
Beyond the preview
Go deeper on Qijian Granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Qijian Granules.